Ali Mohammed Thamer, Chapra Ammar, Mohamed Samah F A, Ghareeb Abdel Naser, Al Kuwari Maryam, Karim Sabir Abdul, Hamid Tahir, Hassan Emad Ahmed Ali, Al Qahtani Awad, Asaad Nidal, Al Suwaidi Jassim
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Department of Clinical Imaging, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Heart Views. 2024 Oct-Dec;25(4):197-211. doi: 10.4103/heartviews.heartviews_62_24. Epub 2025 May 10.
COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination.
To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 vaccination.
We conducted a case series analysis involving 17 patients diagnosed with inflammatory myocarditis.
Symptoms in these patients typically appeared 24-96 h after receiving the COVID-19 mRNA vaccine. Fortunately, the prognosis for these patients is generally favorable, characterized by good short-term recovery and minimal long-term consequences. Follow-up cardiac magnetic resonance imaging (CMR) among our patients revealed alongside a preserved ejection fraction, the absence of fibrosis in 7 out of 13 (54%) patients with minimal residual fibrosis in 5 (38%) patients, whereas the remaining one patient demonstrated fibrosis consistent with hypertrophic cardiomyopathy.
Despite the seemingly benign nature of COVID-19 mRNA vaccine-related myocarditis thus far, it is crucial to emphasize the necessity of prolonged clinical and CMR follow-up exceeding 1 year. Extended monitoring is essential to gain a deeper understanding of the true nature of this condition and its potential implications. This comprehensive approach will contribute significantly to ensuring the ongoing safety and efficacy of COVID-19 vaccination programs.
新型冠状病毒肺炎（COVID-19）信使核糖核酸（mRNA）疫苗相关心肌炎虽罕见，但主要影响年轻男性，且常在接种疫苗后第1周内出现症状。
评估COVID-19疫苗接种后被诊断为心肌炎的个体的长期预后。
我们进行了一项病例系列分析，涉及17例被诊断为炎症性心肌炎的患者。
这些患者的症状通常在接种COVID-19 mRNA疫苗后24 - 96小时出现。幸运的是，这些患者的预后总体良好，其特点是短期恢复良好且长期后果最小。我们患者的随访心脏磁共振成像（CMR）显示，除射血分数保留外，13例患者中有7例（54%）无纤维化，5例（38%）有轻度残留纤维化，而其余1例患者表现出与肥厚型心肌病一致的纤维化。
尽管迄今为止COVID-19 mRNA疫苗相关心肌炎看似性质良性，但强调超过1年的长期临床和CMR随访的必要性至关重要。延长监测对于更深入了解这种疾病的真实性质及其潜在影响至关重要。这种全面的方法将对确保COVID-19疫苗接种计划的持续安全性和有效性做出重大贡献。
